We use cookies for a better user experience. Read our Privacy Policy

I Agree

Prostate Cancer Therapeutics Market

Prostate Cancer Therapeutics Market (Therapy: Hormone Therapy, Chemotherapy, Biologic Therapy, and Targeted Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Prostate Cancer Therapeutics Market Outlook 2031

  • The global prostate cancer therapeutics market was valued at US$ 11.14 Bn in 2021
  • The global market is projected to grow at a CAGR of 6.9% from 2022 to 2031
  • The global prostate cancer therapeutics market is anticipated to reach more than US$ 21.7 Bn by the end of 2031

Analysts’ Viewpoint on Prostate Cancer Therapeutics Market Scenario

Prostate cancer is the most prevalent non-cutaneous cancer in the world. Globally, the prevalence of prostate cancer is driven by aging population, sedentary lifestyle of the people in industrialized countries, and early onset of urological disorders. Research and development activities aimed at sharpening the focus on "patient-centric" care are anticipated to encourage innovation in the form of efficient medications and treatments in this industry. However, dependence of patients on the availability and coverage of reimbursements from health insurance companies could exert pressure on market participants. The previous 10 years have seen significant advancements in prostate cancer therapies, including enzalutamide, abiraterone acetate, sipuleucel-T, cabazitaxel, and radium-233. Patients have high confidence in androgen-independent prostate cancer medications due to fewer adverse effects, which market participants could use to enhance their production rates. Shifting production facilities to emerging Asia Pacific countries could help market participants lower the prices of prostate cancer treatments.

prostate cancer therapeutics market

Prostate Cancer Therapeutics Market Introduction

The global prostate cancer therapeutics market outlook appears positive. Substantial progress has been made in prostate cancer androgen receptor targeting in the past 10 years. The best way to apply immunotherapy and radiopharmaceutical-based treatment in the clinic is yet unknown, but both have made strides. However, the global prostate cancer therapeutics market is likely to be restrained by patients' aversion to expensive cancer therapies and pharmaceuticals. Nevertheless, private and public sector investment in market participants' research and development efforts is projected to propel the global market.

Request a sample to get extensive insights into the Prostate Cancer Therapeutics Market

Rise in Prevalence of Prostate Cancer Driving Global Prostate Cancer Therapeutics Market

Reduced morbidity rates in industrialized economies have led to an increase in the elderly population, which is more prone to prostate cancer. According to the Prostate Cancer Foundation, males over the age of 65 account for the majority of prostate cancer cases.

Thus, increase in the geriatric population, sedentary lifestyle of the people in industrialized countries, and rise in obesity at a young age contribute to the global prevalence of prostate cancer. This increases the need of and demand for prostate cancer therapies.

Launch of Promising Emerging Therapies to Propel Global Market

Advanced diagnostic tools have transformed the diagnosis of prostate cancer. Prostate-specific antigen (PSA) level measurement has aided in the identification of prostate cancer. Novel cytotoxic medicines, hormonal drugs, and other anti-prostate-specific membrane antigen treatments are some of the promising new therapeutics in phase II and phase III studies. According to the Mayo Foundation for Medical Education and Research (MFMER), a combination of hormonal and anti-cytotoxic T-lymphocyte-associated antigen (CTLA) therapy techniques can induce a targeted immune response against prostate cancers.

Request a custom report on Prostate Cancer Therapeutics Market

Less Chance of Cancer Recurrence to Augment Hormone Therapy Segment

In terms of therapy, the global prostate cancer therapeutics market has been classified into hormone therapy, chemotherapy, biologic therapy, and targeted therapy. The hormone therapy segment is anticipated to grow at a rapid pace during the forecast period, as hormone therapy can lessen the chance that cancer will return and stop or slow its growth. Prostate cancer is the fourth most prevalent cancer in both sexes combined, and the second most common cancer in males, according to Globocan. New antiandrogens and luteinizing hormone-releasing hormone antagonists are being introduced in products such as Zytiga and Xtandi.

Large Number of Prostate Cancer Treatments at Hospitals and Simple Reimbursement Procedure to Augment Hospital Pharmacies Segment

Based on distribution channel, the global prostate cancer therapeutics market has been divided into hospital pharmacies, retail pharmacies, and online sales. The hospital pharmacies segment is expected to dominate the global prostate cancer therapeutics market during the forecast period, as large number of prostate cancer treatments are conducted in hospitals and these settings have simple reimbursement procedures.

Regional Outlook of Global Prostate Cancer Therapeutics Market

North America is anticipated to be a highly lucrative market for prostate cancer therapies during the forecast period. This can be ascribed to high cost of newly licensed treatments and rise in disease prevalence in the region. The number of prostate cancer patients is increasing in North America. The U.S.'s large market share and high cost of hormone treatment products are both related. Presence of major companies has increased the number of treatments available in the region.

Europe was the second largest market for prostate cancer therapies in 2021 owing to the high incidence of prostate cancer and rise in awareness about the disease in the region. Growth of the hormone treatment market in Europe can be ascribed to rise in sales of select drugs such as Zytiga and Xtandi. The prostate cancer treatment market in the region is anticipated to be driven by high unmet clinical needs and aging male population. Increase in awareness is also likely to encourage the use of prostate cancer treatments.

Prostate cancer therapies have a sizable market in Asia Pacific. This can be ascribed to the increase in awareness about prostate cancer among patients in the region. Usage of hormone treatment products such as antiandrogens is rising among patients in Asia Pacific, particularly in Japan and China.

Analysis of Key Players in Global Prostate Cancer Therapeutics Market

The global prostate cancer therapeutics market is fragmented, with the presence of a large number of small-scale players. Key players operating in the global prostate cancer therapeutics market include AbbVie, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Dendreon Pharmaceuticals LLC., Endo Pharmaceuticals, Inc., Ipsen Pharma, Johnson & Johnson Services, Inc., Pfizer, Inc., and Sanofi. These players are adopting growth strategies such as new product development, product launches, product approval, agreement, partnerships, and mergers.

Key Developments in Global Prostate Cancer Therapeutics Market

  • In March 2022, Novartis announced the U.S. Food and Drug Administration (FDA) approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer that has spread to other parts of the body
  • In January 2020, Pfizer and Myovant Sciences announced their collaboration to commercialize relugolix, an oral gonadotropin-releasing hormone receptor antagonist. Relugolix (120 mg) is FDA-approved as ORGOVYX for adult patients with advanced prostate cancer. Thus, it helps in advanced prostate cancer treatment.

This global market study on prostate cancer therapeutics profiles each of these players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Prostate Cancer Therapeutics Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 11.14 Bn

Market Forecast Value in 2031

More than US$ 21.7 Bn

Growth Rate (CAGR) 2022-2031

6.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Therapy
    • Hormone Therapy
    • Luteinizing Hormone-releasing Hormone Analogs
    • Luteinizing Hormone-releasing Hormone Antagonists
    • Antiandrogens
    • Chemotherapy
    • Systemic Chemotherapy
    • Regional Chemotherapy
    • Biologic Therapy
    • Targeted Therapy
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Sales
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca
  • Bayer AG
  • Dendreon Pharmaceuticals LLC
  • Endo Pharmaceuticals, Inc.
  • Ipsen Pharma
  • Johnson & Johnson Services
  • Pfizer, Inc.
  • Sanofi

Customization Scope

Available upon request

Pricing

Available upon request

Prostate Cancer Therapeutics Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global prostate cancer therapeutics market in 2021?

The global prostate cancer therapeutics market was valued at US$ 11.14 Bn in 2021.

How big will be the global prostate cancer therapeutics market in 2031?

The global prostate cancer therapeutics market is projected to reach more than US$ 21.7 Bn by 2031.

What was the CAGR of the global prostate cancer therapeutics market from 2017 to 2021?

The global prostate cancer therapeutics market grew at a CAGR of 5.5% from 2017 to 2021.

What will be the CAGR of the global prostate cancer therapeutics market during the forecast period (2022–2031)?

The global prostate cancer therapeutics market is anticipated to grow at a CAGR of 6.9% from 2022 to 2031.

What was the market share of the leading segment of the global prostate cancer therapeutics market?

Hormone therapy was the leading segment of the global prostate cancer therapeutics market, with 80% share in 2021.

Which region will account for major share of the global market during the forecast period?

North America is expected to account for the major share of the global prostate cancer therapeutics market during the forecast period.

Who are the prominent players in the global prostate cancer therapeutics market?

AbbVie, Inc., Amgen, Inc., AstraZeneca, Bayer AG, Dendreon Pharmaceuticals LLC, Endo Pharmaceuticals, Inc., Ipsen Pharma, Johnson & Johnson Services, Inc., Pfizer Inc., and Sanofi.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Prostate Cancer Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Segment Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Prostate Cancer Therapeutics Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key Mergers & Acquisitions

    5.2. Pipeline Analysis

    5.3. Disease Prevalence & Incidence Rate globally with key countries

    5.4. Covid-19 Impact Analysis

6. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Therapy

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Therapy, 2017–2031

        6.3.1. Hormone Therapy

            6.3.1.1. Luteinizing Hormone-releasing Hormone Analogs

            6.3.1.2. Luteinizing Hormone-releasing Hormone Antagonists

            6.3.1.3. Antiandrogens

        6.3.2. Chemotherapy

            6.3.2.1. Systemic Chemotherapy

            6.3.2.2. Regional Chemotherapy

        6.3.3. Biologic Therapy

        6.3.4. Targeted Therapy

    6.4. Market Attractiveness Analysis, by Therapy

7. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Distribution Channel

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2017–2031

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Online Sales

        7.3.4. Others

    7.4. Market Attractiveness Analysis, by Distribution Channel

8. Global Prostate Cancer Therapeutics Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America

        8.2.2. Europe

        8.2.3. Asia Pacific

        8.2.4. Latin America

        8.2.5. Middle East & Africa

    8.3. Market Attractiveness Analysis, by Region

9. North America Prostate Cancer Therapeutics Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Therapy, 2017–2031

        9.2.1. Hormone Therapy

            9.2.1.1. Luteinizing Hormone-releasing Hormone Analogs

            9.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists

            9.2.1.3. Antiandrogens

        9.2.2. Chemotherapy

            9.2.2.1. Systemic Chemotherapy

            9.2.2.2. Regional Chemotherapy

        9.2.3. Biologic Therapy

        9.2.4. Targeted Therapy

    9.3. Market Value Forecast, by Distribution Channel, 2017–2031

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Sales

        9.3.4. Others

    9.4. Market Value Forecast, by Country, 2017–2031

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis

        9.5.1. By Therapy

        9.5.2. By Distribution Channel

        9.5.3. By Country

10. Europe Prostate Cancer Therapeutics Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Therapy, 2017–2031

        10.2.1. Hormone Therapy

            10.2.1.1. Luteinizing Hormone-releasing Hormone Analogs

            10.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists

            10.2.1.3. Antiandrogens

        10.2.2. Chemotherapy

            10.2.2.1. Systemic Chemotherapy

            10.2.2.2. Regional Chemotherapy

        10.2.3. Biologic Therapy

        10.2.4. Targeted Therapy

    10.3. Market Value Forecast, by Distribution Channel, 2017–2031

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Sales

        10.3.4. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Italy

        10.4.5. Spain

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis

        10.5.1. By Therapy

        10.5.2. By Distribution Channel

        10.5.3. By Country/Sub-region

11. Asia Pacific Prostate Cancer Therapeutics Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Therapy, 2017–2031

        11.2.1. Hormone Therapy

            11.2.1.1. Luteinizing Hormone-releasing Hormone Analogs

            11.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists

            11.2.1.3. Antiandrogens

        11.2.2. Chemotherapy

            11.2.2.1. Systemic Chemotherapy

            11.2.2.2. Regional Chemotherapy

        11.2.3. Biologic Therapy

        11.2.4. Targeted Therapy

    11.3. Market Value Forecast, by Distribution Channel, 2017–2031

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Online Sales

        11.3.4. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.4.1. China

        11.4.2. India

        11.4.3. Japan

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis

        11.5.1. By Therapy

        11.5.2. By Distribution Channel

        11.5.3. By Country/Sub-region

12. Latin America Prostate Cancer Therapeutics Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Therapy, 2017–2031

        12.2.1. Hormone Therapy

            12.2.1.1. Luteinizing Hormone-releasing Hormone Analogs

            12.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists

            12.2.1.3. Antiandrogens

        12.2.2. Chemotherapy

            12.2.2.1. Systemic Chemotherapy

            12.2.2.2. Regional Chemotherapy

        12.2.3. Biologic Therapy

        12.2.4. Targeted Therapy

    12.3. Market Value Forecast, by Distribution Channel, 2017–2031

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Online Sales

        12.3.4. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis

        12.5.1. By Therapy

        12.5.2. By Distribution Channel

        12.5.3. By Country/Sub-region

13. Middle East & Africa Prostate Cancer Therapeutics Market Analysis and Forecast

   13.1.Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Therapy, 2017–2031

        13.2.1. Hormone Therapy

            13.2.1.1. Luteinizing Hormone-releasing Hormone Analogs

            13.2.1.2. Luteinizing Hormone-releasing Hormone Antagonists

            13.2.1.3. Antiandrogens

        13.2.2. Chemotherapy

            13.2.2.1. Systemic Chemotherapy

            13.2.2.2. Regional Chemotherapy

        13.2.3. Biologic Therapy

        13.2.4. Targeted Therapy

    13.3. Market Value Forecast, by Distribution Channel, 2017–2031

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Online Sales

        13.3.4. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.4.1. GCC

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis

        13.5.1. By Therapy

        13.5.2. By Distribution Channel

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (by tier and size of companies)

    14.2. Market Share Analysis, by Company, 2021

    14.3. Company Profiles

        14.3.1. AbbVie, Inc.

            14.3.1.1. Company Overview

            14.3.1.2. Financial Overview

            14.3.1.3. Product Portfolio

            14.3.1.4. Business Strategies

            14.3.1.5. Recent Developments

        14.3.2. Amgen, Inc.

            14.3.2.1. Company Overview

            14.3.2.2. Financial Overview

            14.3.2.3. Product Portfolio

            14.3.2.4. Business Strategies

            14.3.2.5. Recent Developments

        14.3.3. AstraZeneca

            14.3.3.1. Company Overview

            14.3.3.2. Financial Overview

            14.3.3.3. Product Portfolio

            14.3.3.4. Business Strategies

            14.3.3.5. Recent Developments

        14.3.4. Bayer AG

            14.3.4.1. Company Overview

            14.3.4.2. Financial Overview

            14.3.4.3. Product Portfolio

            14.3.4.4. Business Strategies

            14.3.4.5. Recent Developments

        14.3.5. Dendreon Pharmaceuticals LLC

            14.3.5.1. Company Overview

            14.3.5.2. Financial Overview

            14.3.5.3. Product Portfolio

            14.3.5.4. Business Strategies

            14.3.5.5. Recent Developments

        14.3.6. Endo Pharmaceuticals, Inc.

            14.3.6.1. Company Overview

            14.3.6.2. Financial Overview

            14.3.6.3. Product Portfolio

            14.3.6.4. Business Strategies

            14.3.6.5. Recent Developments

        14.3.7. Ipsen Pharma

            14.3.7.1. Company Overview

            14.3.7.2. Financial Overview

            14.3.7.3. Product Portfolio

            14.3.7.4. Business Strategies

            14.3.7.5. Recent Developments

        14.3.8. Johnson & Johnson Services, Inc.

            14.3.8.1. Company Overview

            14.3.8.2. Financial Overview

            14.3.8.3. Product Portfolio

            14.3.8.4. Business Strategies

            14.3.8.5. Recent Developments

        14.3.9. Pfizer Inc.

            14.3.9.1. Company Overview

            14.3.9.2. Financial Overview

            14.3.9.3. Product Portfolio

            14.3.9.4. Business Strategies

            14.3.9.5. Recent Developments

        14.3.10. Sanofi

            14.3.10.1. Company Overview

            14.3.10.2. Financial Overview

            14.3.10.3. Product Portfolio

            14.3.10.4. Business Strategies

            14.3.10.5. Recent Developments

        14.3.11. Other Prominent Players

List of Tables

Table 1: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031

Table 2: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031

Table 3: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031

Table 4: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 5: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017–2031

Table 6: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031

Table 7: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031

Table 8: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031

Table 9: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast,  by Country, 2017–2031

Table 11: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031

Table 12: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031

Table 13: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy,  2017–2031

Table 14: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 15: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031

Table 17: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031

Table 18: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031

Table 19: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 20: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031

Table 22: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031

Table 23: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy, 2017–2031

Table 24: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 25: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Therapy, 2017–2031

Table 27: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Hormone Therapy, 2017–2031

Table 28: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Chemotherapy (Therapy), 2017–2031

Table 29: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 30: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 1: Global Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast, 2017–2032

Figure 2: Global Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031

Figure 3: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hormone Therapy 2017–2031

Figure 4: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy 2017–2031

Figure 5: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Biologic Therapy 2017–2031

Figure 6: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy 2017–2031

Figure 7: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031

Figure 8: Global Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031

Figure 9: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies 2017–2031

Figure 10: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2031

Figure 11: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Sales, 2017–2031

Figure 12: Global Prostate Cancer Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 13: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 14: Global Prostate Cancer Therapeutics Market Value Share, by Region, 2017 and 2031

Figure 15: Global Prostate Cancer Therapeutics Market Attractiveness Analysis, by Region, 2022–2031

Figure 16: North America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 17: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country, 2022–2031

Figure 18: North America Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031

Figure 19: North America Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031

Figure 20: North America Prostate Cancer Therapeutics Market Value Share, by Country, 2017 and 2031

Figure 21: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031

Figure 22: North America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 23: Europe Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 24: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 25: Europe Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031

Figure 26: Europe Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031

Figure 27: Europe Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031

Figure 28: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 20122-2031

Figure 29: Europe Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 30: Asia Pacific Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 31: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 32: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031

Figure 33: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031

Figure 34: Asia Pacific Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031

Figure 35: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031

Figure 36: Asia Pacific Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2031

Figure 37: Latin America Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 38: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 39: Latin America Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031

Figure 40: Latin America Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031

Figure 41: Latin America Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031

Figure 42: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031

Figure 43: Latin America Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 44: Middle East & Africa Prostate Cancer Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 45: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 46: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Therapy, 2017 and 2031

Figure 47: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Distribution Channel, 2017 and 2031

Figure 48: Middle East & Africa Prostate Cancer Therapeutics Market Value Share, by Country/Sub-region, 2017 and 2031

Figure 49: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Therapy, 2022–2031

Figure 50: Middle East & Africa Prostate Cancer Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2031

Figure 51: Global Prostate Cancer Therapeutics Market Share Analysis, by Company, 2021(Estimated)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

109

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved